---
title: "Diabetes After Solid-Organ Transplant: Multi‑Organ Registry Findings from ENDO 2026"
id: "endocrine-news-0-looking-across-the-organs-diabetes-after-transplant"
canonical_url: "https://medichelpline.com/clinical-feed/endocrine-news-0-looking-across-the-organs-diabetes-after-transplant"
content_type: "clinical_feed_article"
specialty: "Endocrinology"
source_name: "Endocrine News"
source_url: "https://endocrinenews.endocrine.org/looking-across-the-organs-diabetes-after-transplant/"
published_at: "2026-11-13T14:36:48.000Z"
evidence_level: "Verified Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# Diabetes After Solid-Organ Transplant: Multi‑Organ Registry Findings from ENDO 2026
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/endocrine-news-0-looking-across-the-organs-diabetes-after-transplant
- **Specialty:** [Endocrinology](https://medichelpline.com/clinical-feed/endocrinology.md)
- **Primary Source:** Endocrine News
- **Source URL:** [Original Journal Publication](https://endocrinenews.endocrine.org/looking-across-the-organs-diabetes-after-transplant/)
- **Published At:** 2026-11-13T14:36:48.000Z
- **Evidence Rating:** Verified Feed
## Executive GIST (TL;DR)
- Investigators analyzed Organ Procurement and Transplantation Network registry data covering 1987–2021 to compare baseline diabetes prevalence, new‑onset diabetes after transplant (NODAT) incidence, and mortality across kidney, liver, heart, and lung recipients. - The cohort totaled 803,762 transplant recipients, and the study team stratified outcomes by diabetes status at baseline versus NODAT during follow‑up; the source reported these sample and time-frame details. - **Diabetes** increased long‑term mortality across all organ types, with baseline and NODAT showing similar aggregate effects on survival. - Organ-specific patterns differed markedly: kidney and liver recipients with preexisting diabetes faced higher mortality than those developing NODAT, while heart and lung recipients experienced greater mortality associated with NODAT. - Thoracic recipients (heart and lung) had higher cumulative incidence of NODAT, with a noticeable rise around one year post‑transplant, according to the investigators’ non‑cumulative time‑window analysis. - Authors noted mechanistic hypotheses focused on immunosuppression: glucocorticoid‑induced insulin resistance and calcineurin inhibitor–related beta‑cell toxicity were cited as contributors, and immunosuppression intensity varies by organ. - The study team plans further work: stratification by immunosuppression regimen, adding data through 2025, examining organ‑specific etiologies, developing a prognosticator for NODAT risk, and pilot use of continuous glucose monitors and oral glucose tolerance tests at their center. - Hutchison noted collaboration with the FDA on a small molecule that may delay post‑transplant diabetes; the source reported no additional trial details or outcomes for that agent. - Limitations described in the source include reliance on registry data and the need for additional stratification by immunosuppression and etiologies; the source indicated a manuscript is in preparation but did not provide publication details.
## Clinical Analysis & Structured Key Points
[Skip to content](https://endocrinenews.endocrine.org/looking-across-the-organs-diabetes-after-transplant/#wp--skip-link--target) [Endocrine News](https://endocrinenews.endocrine.org) [![Endocrine News](https://endocrinenews.endocrine.org/wp-content/uploads/es-reversed.svg)](https://endocrinenews.endocrine.org/) * [Topics](https://endocrinenews.endocrine.org/category/health-topic/diabetes/) * [Diabetes](https://endocrinenews.endocrine.org/category/health-topic/diabetes/) * [Obesity](https://endocrinenews.endocrine.org/category/health-topic/obesity/) * [Adrenal](https://endocrinenews.endocrine.org/category/health-topic/adrenal/) * [Bone and Mineral](https://endocrinenews.endocrine.org/category/health-topic/bone-and-mineral/) * [Cardiometabolic](https://endocrinenews.endocrine.org/category/health-topic/cardiometabolic/) * [Endocrine Disruptors](https://endocrinenews.endocrine.org/category/health-topic/endocrine-disruptors/) * [Head Glands](https://endocrinenews.endocrine.org/category/health-topic/head-glands/) * [Kidney Issues](https://endocrinenews.endocrine.org/category/health-topic/kidney-issues/) * [Neoplasia and Cancer](https://endocrinenews.endocrine.org/category/health-topic/neoplasia-and-cancer/) * [Pancreas](https://endocrinenews.endocrine.org/category/health-topic/pancreas/) * [Reproductive Issues](https://endocrinenews.endocrine.org/category/health-topic/reproductive-issues/) * [Thyroid](https://endocrinenews.endocrine.org/category/health-topic/thyroid/) * [Pediatric Health](https://endocrinenews.endocrine.org/category/patient-populations/pediatric-health/) * [Men’s Health](https://endocrinenews.endocrine.org/category/patient-populations/mens-health/) * [Women’s Health](https://endocrinenews.endocrine.org/category/patient-populations/womens-health/) * [Why Endocrinology?](https://endocrinenews.endocrine.org/category/why-endocrinology/) * [Practice](https://endocrinenews.endocrine.org/category/practice/) * [Your Practice](https://endocrinenews.endocrine.org/category/practice/your-practice/) * [Your Patients](https://endocrinenews.endocrine.org/category/practice/your-patients/) * [Product / Technology](https://endocrinenews.endocrine.org/category/practice/product-technology/) * [Endocrinology Workforce](https://endocrinenews.endocrine.org/category/endocrinology-workforce/) * [Lab Notes](https://endocrinenews.endocrine.org/category/lab-notes/) * [Q&A](https://endocrinenews.endocrine.org/category/lab-notes/q-a/) * [Your Laboratory](https://endocrinenews.endocrine.org/category/your-laboratory/) * [Products and Technological Advancements in Endocrinology](https://endocrinenews.endocrine.org/category/lab-notes/products-technology/) * [Advocacy](https://endocrinenews.endocrine.org/category/advocacy/) * [Clinical](https://endocrinenews.endocrine.org/category/advocacy/clinical/) * [Research](https://endocrinenews.endocrine.org/category/advocacy/research/) * [InTouch](https://endocrinenews.endocrine.org/intouch/) * [Member News](https://endocrinenews.endocrine.org/category/in-touch/member-news-in-touch/) * [Society News](https://endocrinenews.endocrine.org/category/in-touch/society-news/) * [Podcast](https://www.endocrine.org/podcast) * [Current Issue Download](https://endocrinenews.endocrine.org/magazine/current-issue/) * [My Profile](https://ams.endocrine.org/eweb/) * [Log In](https://endocrinenews.endocrine.org/auth/login) * [Log Out](https://endocrinenews.endocrine.org/auth/logout) * [Topics](https://endocrinenews.endocrine.org/category/health-topic/diabetes/) * [Diabetes](https://endocrinenews.endocrine.org/category/health-topic/diabetes/) * [Obesity](https://endocrinenews.endocrine.org/category/health-topic/obesity/) * [Adrenal](https://endocrinenews.endocrine.org/category/health-topic/adrenal/) * [Bone and Mineral](https://endocrinenews.endocrine.org/category/health-topic/bone-and-mineral/) * [Cardiometabolic](https://endocrinenews.endocrine.org/category/health-topic/cardiometabolic/) * [Endocrine Disruptors](https://endocrinenews.endocrine.org/category/health-topic/endocrine-disruptors/) * [Head Glands](https://endocrinenews.endocrine.org/category/health-topic/head-glands/) * [Kidney Issues](https://endocrinenews.endocrine.org/category/health-topic/kidney-issues/) * [Neoplasia and Cancer](https://endocrinenews.endocrine.org/category/health-topic/neoplasia-and-cancer/) * [Pancreas](https://endocrinenews.endocrine.org/category/health-topic/pancreas/) * [Reproductive Issues](https://endocrinenews.endocrine.org/category/health-topic/reproductive-issues/) * [Thyroid](https://endocrinenews.endocrine.org/category/health-topic/thyroid/) * [Pediatric Health](https://endocrinenews.endocrine.org/category/patient-populations/pediatric-health/) * [Men’s Health](https://endocrinenews.endocrine.org/category/patient-populations/mens-health/) * [Women’s Health](https://endocrinenews.endocrine.org/category/patient-populations/womens-health/) * [Why Endocrinology?](https://endocrinenews.endocrine.org/category/why-endocrinology/) * [Practice](https://endocrinenews.endocrine.org/category/practice/) * [Your Practice](https://endocrinenews.endocrine.org/category/practice/your-practice/) * [Your Patients](https://endocrinenews.endocrine.org/category/practice/your-patients/) * [Product / Technology](https://endocrinenews.endocrine.org/category/practice/product-technology/) * [Endocrinology Workforce](https://endocrinenews.endocrine.org/category/endocrinology-workforce/) * [Lab Notes](https://endocrinenews.endocrine.org/category/lab-notes/) * [Q&A](https://endocrinenews.endocrine.org/category/lab-notes/q-a/) * [Your Laboratory](https://endocrinenews.endocrine.org/category/your-laboratory/) * [Products and Technological Advancements in Endocrinology](https://endocrinenews.endocrine.org/category/lab-notes/products-technology/) * [Advocacy](https://endocrinenews.endocrine.org/category/advocacy/) * [Clinical](https://endocrinenews.endocrine.org/category/advocacy/clinical/) * [Research](https://endocrinenews.endocrine.org/category/advocacy/research/) * [InTouch](https://endocrinenews.endocrine.org/intouch/) * [Member News](https://endocrinenews.endocrine.org/category/in-touch/member-news-in-touch/) * [Society News](https://endocrinenews.endocrine.org/category/in-touch/society-news/) * [Podcast](https://www.endocrine.org/podcast) * [Current Issue Download](https://endocrinenews.endocrine.org/magazine/current-issue/) * [My Profile](https://ams.endocrine.org/eweb/) * [Log In](https://endocrinenews.endocrine.org/auth/login) * [Log Out](https://endocrinenews.endocrine.org/auth/logout) Search Search [Current Issue Download](https://endocrinenews.endocrine.org/magazine-issues/november-2026/) [Login](https://endocrinenews.endocrine.org/auth/login/?redirect=https://endocrinenews.endocrine.org/looking-across-the-organs-diabetes-after-transplant/) ![](https://endocrinenews.endocrine.org/wp-content/themes/mg-starter/assets/images/Endocrine_News_standard_logo.svg) * * * # Looking Across the Organs: Diabetes After Transplant By Kelly Horvath November 13, 2026 Print this article Share this article ![](https://endocrinenews.endocrine.org/wp-content/uploads/organ-cooler-scaled.jpg) ##### Cross-organ research examines how preexisting diabetes and new-onset diabetes affect survival after kidney, liver, heart, and lung transplantation. Research presented at **ENDO 2026** last June highlights distinct organ-specific risks and calls for prevention, monitoring, and long-term care beyond the transplant procedure itself. The presence of diabetes negatively impacts almost any co-occurring health problem, including organ transplantation. Although this impact varies widely across organ transplant types, research into how and why remains siloed within the respective fields. “Diabetes Burden and Mortality in Solid Organ Transplantation: A Comprehensive Multi-Organ Analysis,” presented last June at **ENDO 2026** in Chicago, Ill., gets needed crosstalk going among kidney, liver, heart, and lung transplant specialties. Study lead and presenter Mishal Ali, graduate researcher at the University of Chicago in Chicago, Ill., and her research supervisor Alan L. Hutchison, MD, PhD, who is also a transplant hepatologist at UChicago Medicine, performed a comprehensive multi-organ analysis to characterize diabetes epidemiology and survival outcomes in solid organ transplant recipients. **At a Glance** • Diabetes substantially increases long-term mortality across all major organ transplants, with both baseline and new-onset diabetes (NODAT) showing comparable impact overall. • In organ-specific analyses, the association of type of diabetes diagnosis varied 6.8-fold, with liver and kidney transplant recipients with preexisting diabetes vs. NODAT facing higher mortality risk, and heart and lung transplant recipients facing higher risk from NODAT. • The variation in diabetes burden emphasizes the need for long-term organ-specific prevention and management strategies. ## **Medical Catch-22** While organ transplant teams have long accepted that the treatments that sustain an organ transplant can worsen preexisting diabetes or cause new-onset diabetes (NODAT), any organ-specific factors remained unelucidated. The two main hypotheses for what causes this medical catch-22 both relate to the necessary immunosuppression individuals must undergo post-transplant to prevent their immune system from attacking the transplanted organ. Hutchison explains: “Glucocorticoids can worsen insulin resistance, so given the same amount of carbohydrate or sugar exposure, the body is not as adept at handling it. The calcineurin inhibitors tacrolimus and cyclosporine are central to long-term graft survival, but those same mechanisms that prevent T cells from attacking the transplanted organ underlie how beta cells in the pancreas release insulin, so a side effect of these medications is damage to the beta cells that produce and release insulin.” There is another huge catch — earlier attempts to reduce the risk of developing or worsening diabetes by adjusting immunosuppression increased organ rejection and mortality rates. ![](https://endocrinenews.endocrine.org/wp-content/uploads/Mishal-Ali-2025-Headshot.jpeg) > “Generally across our population, after receiving a transplant, what was the incidence of [new-onset diabetes] across 15 years? We looked at that across organs, and we noticed that thoracic recipients, people who received lung or heart transplants, were more likely to develop diabetes than the other organs we compared against. About one in four lung and heart recipients would develop diabetes.” > Mishal Ali, graduate researcher, University of Chicago, Chicago, Ill. The field was more or less stuck at this impasse until now. Explains Hutchison: “I realized that the liver doctors, kidney doctors, lung doctors, and heart doctors were all talking among themselves about this, in the literature and in their centers and in their databases, and nobody was really pulling all the data together to look across all the organs and ask, are there common trends? Is it all immunosuppression? Are there other factors at play?” Answering these key questions requires more data than any one organ program can supply. He believes that combining the data from all four solid organs will provide insight into what interventions clinicians could make pre-transplant to increase the chance of transplant success. “Can we predict beforehand who’s going to develop diabetes using physiologic signals? Can we create a personalized plan for them before they even have the transplant?” ## **Results of the Multi-Organ Analysis** Using registry data from the federal Organ Procurement and Transplantation Network, Ali and Hutchison analyzed data from 803,762 transplant recipients, assessing baseline diabetes prevalence, NODAT incidence, and mortality stratified by diabetes status. “We started off with a general analysis of our cohorts,” explains Ali. “Looking at our entire transplantation cohort from 1987 all the way until 2021, what was the level of baseline diabetes for each of the solid organ transplants, and did that level change? The highest prevalence was recorded in kidney, meaning that one in three kidney recipients were already diabetic at the time of transplant.” Among patients with no history of diabetes, a different pattern emerged. Says Ali: “The next important thing was, generally across our population, after receiving a transplant, what was the incidence of NODAT across 15 years? We looked at that across organs, and we noticed that thoracic recipients, people who received lung or heart transplants, were more likely to develop diabetes than the other organs we compared against. About one in four lung and heart recipients would develop diabetes.” As to what causes diabetes to develop vs. worsen in heart and lung transplant recipients, Ali points to the underlying diseases that necessitate transplant. Cystic fibrosis, for example, is a leading cause of lung transplant. Because it also affects the pancreas, this suggests that diabetes was possibly present but undiagnosed pre-transplant or that even though the patient received a lung transplant, the disease process has since progressed in the pancreas. Immunosuppression intensity may also play a part, since lung and heart patients generally need more than liver patients, and the physiology of organ failure may mask diabetes beforehand. ![](https://endocrinenews.endocrine.org/wp-content/uploads/handful-of-organs-1024x448.jpg) Ali’s analysis split the post-transplant period into non-cumulative windows, with a stark rise in NODAT in heart and lung recipients around the one-year mark. Hutchison acknowledges that comparing the first year with years one through five is not entirely fair, but says the breakdown makes a point. “In transplant we’re very focused on survival at one year. Breaking it down this way highlights that the side effects of the things we’ve done to save patients’ lives persist and that these patients’ journeys are not done.” Otherwise, patients and their primary care providers (PCPs), whom they eventually return to, may not be aware of the elevated risk of developing diabetes. After the first year, the main driver of mortality for all transplant recipients is cardiovascular disease, and diabetes and metabolic syndrome account for a large amount of that. “There’s either something we can do differently in that first year,” he says, “or at the very least, their PCPs should know this is somebody they have to pay extra attention to.” The preexisting vs. NODAT analysis revealed some surprises. “It looks like pre-existing diabetes for kidney and liver recipients, especially kidney, carries a significantly higher mortality risk than developing diabetes after transplant,” Ali says. This makes sense biologically, insofar as patients with preexisting diabetes have a slightly lower health baseline at time of transplant, which can prolong recovery, and the added immunosuppression can cause the situation to further deteriorate. On the flipside, the prognosis for recipients who develop NODAT is somewhat more promising. The opposite dynamic was seen with thoracic organ recipients, with NODAT conferring higher mortality risk. “We were surprised to see that for heart and lung, and more so for heart, new-onset diabetes carries a higher mortality risk than pre-existing diabetes,” says Ali. Using Kaplan-Meier survival analysis and Cox proportional hazards regression and adjusting for age, year of transplant, body mass index, and sex, a 6.8-fold variation in diabetes burden emerged, emphasizing the need for organ-specific prevention and management strategies but also underscoring the importance of having cross-organ comparisons to draw on. ## **Future Directions** Hutchison sums it up this way: “If NODAT is almost as bad for your mortality as having diabetes beforehand, there’s really a mandate to figure this out and not just wait for it to happen and be reactive.” In practice, he says, much of the answer starts with communication and education. “Our patients are great advocates for themselves, and we remind them of the importance of getting a hemoglobin A1c every three months. ‘You’ve got a second lease on life, but now you’ve got to put in the work.’” The longer-term goal is better tools, and Hutchison and Ali have several projects underway. One is a prognosticator to estimate the chance that a transplant patient will develop diabetes at one year, one to five years, or five to 10 years, building from the national registries to UChicago’s own database and then to collaborating institutions. At UChicago, Hutchison’s group is also giving transplant candidates and recipients continuous glucose monitors and oral glucose tolerance tests to improve diagnosis and detection. Hutchison is working with the U.S. Food and Drug Administration on a small molecule that may delay post-transplant diabetes; it has shown some efficacy in delaying type 1 diabetes and is already approved for other indications. Ali’s next steps include stratifying by immunosuppression regimen, adding data through 2025, and examining specific etiologies within each organ, and the team is preparing a manuscript. Hutchison is also training as a junior methodologist with the American Association for the Study of Liver Diseases with the eventual aim of his transplant and diabetes work making it into clinical practice guidelines — a “25-year goal.” ![](https://endocrinenews.endocrine.org/wp-content/uploads/Alan-ACG-headshot.jpg) > “Glucocorticoids can worsen insulin resistance, so given the same amount of carbohydrate or sugar exposure, the body is not as adept at handling it. The calcineurin inhibitors tacrolimus and cyclosporine are central to long-term graft survival, but those same mechanisms that prevent T cells from attacking the transplanted organ underlie how beta cells in the pancreas release insulin, so a side effect of these medications is damage to the beta cells that produce and release insulin.” > Alan L. Hutchison, MD, PhD, transplant hepatologist. University of Chicago Medicine, Chicago, Ill. The presentation drew a strong response. Ali recalls that most of the audience questions concerned the patterns within each organ and what the underlying mechanisms might be. “It was really great,” she says. “The response was overwhelmingly positive, and it’s very nice to see how much people genuinely care about this.” Hutchison sees “a lot of energy in better understanding post-transplant endocrinopathies and post-transplant diabetes in particular,” and he and Ali have submitted a post-transplant diabetes proposal for **ENDO 2027**. Discussion for a formal transplant endocrinology subgroup at the Endocrine Society is also ongoing. Ultimately, Hutchison and Ali hope to broaden the focus of transplant care. The “big moment” when a transplant happens is obviously important, but transplantation does not actually end there. “What matters is how patients do over the long term,” says Hutchison, “and that applies to both their care and funding research. The field needs to also focus on all the care and thought that needs to go in before and after to make it viable and sustainable.” _Horvath is a freelance writer based in Baltimore, Md. In the October issue, she wrote “_** _Closing Windows of Vulnerability: EDC Exposure During Development_** _” about how early-life exposure to endocrine-disrupting chemicals can affect various endocrine functions._ * * * ## TOPICS IN THIS ARTICLE: [Diabetes News and Research](https://endocrinenews.endocrine.org/category/diabetes-news-and-research/)[Kidney Issues](https://endocrinenews.endocrine.org/category/health-topic/kidney-issues/) ←[DECA B
## Related Clinical Research

- [Preconception, Gestational, and Postpartum Care for Type 2 Diabetes](https://medichelpline.com/clinical-feed/endocrine-news-0-preconception-gestational-and-postpartum-care.md)
- [Endocrine Society Launches Diabetes SIG and Expands Education, Research, Advocacy](https://medichelpline.com/clinical-feed/endocrine-news-1-society-offers-full-spectrum-of-diabetes-resources-including-a-new-sig-for.md)
- [High blood pressure in Ugandan children and adolescents with Type 1 diabetes: multicenter prevalen](https://medichelpline.com/clinical-feed/plos-one-11-high-blood-pressure-among-children-and-adolescents-with-type-1-diabetes.md)
- [Scalable encapsulation of pluripotent stem cell-derived islets in high-concentration alginate bead](https://medichelpline.com/clinical-feed/biorxiv-13-bridging-scale-up-to-transplantation-pluripotent-stem-cell-derived-pancreatic.md)
- [Undiagnosed type 2 diabetes presenting as DKA with hypertriglyceridemia-induced acute pancreatitis](https://medichelpline.com/clinical-feed/cmaj-1-undiagnosed-type-2-diabetes-presenting-as-diabetic-ketoacidosis-with.md)

## Navigation
- [← Back to Endocrinology Feed](https://medichelpline.com/clinical-feed/endocrinology.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.